Japan’s Ono Pharmaceutical has agreed to transfer the manufacturing and marketing approval authorization for Kinedak to Osaka-based Alfresa Pharma. 1 February 2021
Japan’s Eisai has launched the Parkinson’s disease treatment Equfina (safinamide) in South Korea. It is the first launch of Equfina in the Asian region outside of Japan. 1 February 2021
The European Commission has reversed its decision to trigger an emergency provision in the Brexit deal to control COVID-19 vaccine exports from the European Union that was announced on Friday
. 31 January 2021
Seattle-based Lumen Bioscience has announced the launch of a project costing up to $14.5 million funded by CARB-X to develop an oral monoclonal antibody cocktail to prevent serious diarrheal diseases. 27 January 2021
Shares of Adamis Pharmaceuticals leapt a massive 41% to $1.79 on Friday, after the company announced that its Symjepi (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program. 25 January 2021
The US affiliate of Italian family-owned drugmaker Chiesi has announced the appointment of Jason Beyer as VP and head of neonatology and cystic fibrosis, and Jay Meyer as VP and head of the cardiovascular hospital business unit. 22 January 2021
The European Medicines Agency (EMA) has published an overview of its key recommendations in 2020 on the authorization and safety monitoring of medicines for human use. 21 January 2021
The Russian Direct Investment Fund (RDIF) confirms that the Scientific Review was held yesterday between its COVID-19 vaccine Sputnik V and European Medicines Agency (EMA) scientific teams. 20 January 2021
A new company focused on immunological and inflammatory diseases, dubbed Vera Therapeutics, has launched with $80 million in series C financing led by Abingworth LLP. 19 January 2021
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and leading Brazilian pharma União Química have agreed to supply to the country 10 million doses of the world's first registered vaccine against coronavirus Sputnik V in the first quarter of 2021 with deliveries beginning in January. 13 January 2021
French pharma company governed by a non-profit foundation Servier and X-Chem, a US privately held drug discovery company announced today a partnership to identify and develop novel small molecules for the treatment of neurological disorders. 6 January 2021
The Colombian government has announced that it has agreed to buy nine million doses of the COVID-19 vaccine candidate being developed by US healthcare giant Johnson & Johnson. 31 December 2020
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and the Health Supply Center (Central de Abastecimiento y Suministros de Salud, CEASS) of Bolivia have entered into an agreement to supply the country with 2.6 million doses of Sputnik V, the COVID-19 vaccine developed by Russia. 30 December 2020
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against the novel coronavirus, COVID-19, by The National Administration of Drugs, Foods and Medical Devices of Argentina (ANMAT). 24 December 2020
US pharma giant Pfizer has signed an agreement with Russian drugmaker Pharmstandard on the production of four of its anti-cancer drugs at the facilities of the Russian company in the Ufa region. 22 December 2020
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024